Corporate Presentation
Obesity
...and that success of future weight-loss medications
will be determined by differentiation on multiple fronts
Examples of differentiation factors
ZEAL&
ZEALAND PHARMA
GLP-1 backbone
GLP-1 mono
GLP-1/GIP
GLP-1/GCGa
GLP-1/GIP/GCG
GLP-1/GLP-2a
Amylina
Other?
во
HD
Effects on obesity-related comorbidities
Improved tolerability by addressing GI side effects
Unique non-incretin mechanisms, addressing quality of weight
loss for weight maintenance (incl. preservation of muscle mass)
Offer greater convenience through dosing regimen and/or
delivery method
Develop fixed or loose 'flexible-use' combinations for patient
segments that need the highest weight loss
aZealand Pharma clinical development pipeline.
Content developed by Zealand Pharma.
GCG-glucagon; Gl=gastrointestinal; GIP=gastric inhibitory polypeptide; GLP-1-glucagon-like peptide-1; GLP-2-glucagon-like peptide-2.
10View entire presentation